



Redsense releases BioStock CEO interview following Q3 2025 report

Halmstad, Sweden, November 19, 2025 – Redsense Medical AB (publ) (“Redsense” or “the Company”) announces that a video interview with CEO Sebastien Bollue has been published by BioStock.

In the interview, Sebastien Bollue comments on the recently released Q3 2025 report, reflects on his tenure as CEO, and provides a short outlook.

The interview is available at the following link: <http://biostock.se/2025/11/redsense-medical-vi-har-ett-valdigt-starkt-fokus-framat/>

It is also accessible via the BioStock website: www.biostock.se

Contact information

For more information, please contact:
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: [sebastien.bollue \(at\) redsensemecial.com](mailto:sebastien.bollue@redsensemecial.com)

Redsense Medical AB (publ), 556646-4862

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS)